Synagis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.

Regeneron drops RSV drug

At the moment the only approved prophylaxis against the virus is AZ's Synagis (palivizumab) which brought in $677m in sales last year. ... Synagis has previously been a $1bn-plus product, but has seen its sales shrink thanks to the start of generic

Sanofi buys into AZ drug for preventing RSV infections

The deal also includes up to 495m in development and sales milestone payments and focuses on MEDI8897, a follow-up to AZ's already-marketed Synagis (palivizumab) which is the first ... Synagis brought in $677m in sales for AZ last year, with sales down

AZ slims down again with sale of antibiotics to Pfizer

The agreement does not include biologic anti-infective products coming from AZ's Medimmune unit - notably Synagis (palivizumab) for respiratory syncytial virus (RSV) infections and flu vaccine FluMist - or indeed a

Result pages: 1 | 2 | 3 | 4 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director or Senior Account Director: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Senior Medical Writer: Salary is DOE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Graduate Scientific Editor: DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Medical Writer - Creative and Scientific Projects: DOE

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Market Access Consultant - Greater Manchester: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director, Healthcare Advertising Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Associate Scientific Director: Salary TBC

Systematic Review Lead- London: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager- 4 days per week or full-time: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....